Bengaluru, NFAPost: BDR Pharma had earlier received approval from Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to the moderate patients with Covid-19 symptoms under the brand name BDFAVI.
BDFAVI is currently available in 200 mg tablets with a strip of 10 tablets. The 400 mg version is an attempt to reduce the pill burden that has been a demand from doctors and patients to be used for the treatment of mild to moderate Covid-19 patients.
BDR Pharma has persistently been at the forefront in supporting India’s fight against Covid-19. In the short span of 4 months the company has launched 2 path-breaking drugs, to meet the increasing patients’ needs and provide timely therapy options during the pandemic.
Favipiravir, an antiviral drug used for the treatment of influenza in Japan since 2014, was approved by Drug Controller General of India for the treatment of mild to moderate cases of Covid-19 in India.
BDR Pharma CMD Dharmesh Shah said the company aims to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis.
“We will continue research and innovate new treatment options for Covid-19 patients. Introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers,” said BDR Pharma CMD Dharmesh Shah.
Favipiravir confirmed encouraging clinical evidence, with positive results in mild to moderate Covid-19 cases. BDFAVI is priced at Rs 990 for one strip of 10 tablets. The highest safety protocols are met with the manufacturing of BDFAVI to meet national and international demands.
BDR is recognised as a “niche” player in the manufacturing of Pharmaceutical APIs and for the renowned new age formulations. BDR Group of companies has grown steadily in the pharmaceutical industry over the last 15 years, in both domestic and international arenas.
The group is complemented majorly by its two companies – BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.
BDR Group focuses on development in 6 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, Dermatology and Women’s Health which are its dream segment.